SCHEMBL3521733

SCHEMBL3521733

O=C(O)c1c(O)c(-c2cccc(F)c2)cc2nc(-c3ccc(F)c(F)c3)cnc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP1 P11387 1/20 0.42
KMO O15229 4/20 0.41
BCHE P06276 1/20 0.41
ACHE P22303 1/20 0.41
ATR Q13535 1/20 0.39
DHODH Q02127 5/20 0.39
TOP2A P11388 1/20 0.37
FYN P06241 2/20 0.37
HPGDS O60760 1/20 0.37
WNT3A P56704 1/20 0.36
PLK4 O00444 1/20 0.35
AURKA O14965 1/20 0.35
DAPK3 O43293 1/20 0.35
CHEK2 O96017 1/20 0.35
CDK1 P06493 1/20 0.35
PIM1 P11309 1/20 0.35
CDK2 P24941 1/20 0.35
FLT4 P35916 1/20 0.35
KDR P35968 1/20 0.35
MAPK9 P45984 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3522596 0.93 KMO (0.45) TOP1KMODHODHDYRK1A
SCHEMBL3756274 0.87 EGLN3 (0.52) TOP1ATRWNT3A
SCHEMBL3521131 0.83 RXFP1 (0.40) TOP1KMODHODH
SCHEMBL3526186 0.82 KMO (0.40) KMOBCHEACHEDHODHTOP2A
SCHEMBL3518154 0.82 RXFP1 (0.41) TOP1KMOFYN
SCHEMBL3520873 0.81 EGLN3 (0.40) ATRDHODHTOP2AWNT3ACSNK1D
SCHEMBL3523288 0.81 KMO (0.44) TOP1KMODHODH
SCHEMBL3518064 0.80 SMN1; SMN2 (0.42) TOP1BCHEDHODHKDR
SCHEMBL3518053 0.80 RPS6KB1 (0.39) TOP1BCHEACHEATRDHODH
SCHEMBL3761128 0.80 EGLN3 (0.55) TOP1BCHEACHEATR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 EP disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305133-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 TOP1 1959/4885KMO 350/4885BCHE 3932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.